232 related articles for article (PubMed ID: 16166641)
1. New functions of the major histocompatibility complex class II-specific transcription factor RFXANK revealed by a high-resolution mutagenesis study.
Krawczyk M; Masternak K; Zufferey M; Barras E; Reith W
Mol Cell Biol; 2005 Oct; 25(19):8607-18. PubMed ID: 16166641
[TBL] [Abstract][Full Text] [Related]
2. Kaposi's Sarcoma-Associated Herpesvirus Latency-Associated Nuclear Antigen Inhibits Major Histocompatibility Complex Class II Expression by Disrupting Enhanceosome Assembly through Binding with the Regulatory Factor X Complex.
Thakker S; Purushothaman P; Gupta N; Challa S; Cai Q; Verma SC
J Virol; 2015 May; 89(10):5536-56. PubMed ID: 25740990
[TBL] [Abstract][Full Text] [Related]
3. Analysis of ankyrin repeats reveals how a single point mutation in RFXANK results in bare lymphocyte syndrome.
Nekrep N; Geyer M; Jabrane-Ferrat N; Peterlin BM
Mol Cell Biol; 2001 Aug; 21(16):5566-76. PubMed ID: 11463838
[TBL] [Abstract][Full Text] [Related]
4. Conserved residues of the bare lymphocyte syndrome transcription factor RFXAP determine coordinate MHC class II expression.
Long AB; Ferguson AM; Majumder P; Nagarajan UM; Boss JM
Mol Immunol; 2006 Feb; 43(5):395-409. PubMed ID: 16337482
[TBL] [Abstract][Full Text] [Related]
5. Novel mutations in the RFXANK gene: RFX complex containing in-vitro-generated RFXANK mutant binds the promoter without transactivating MHC II.
Wiszniewski W; Fondaneche MC; Louise-Plence P; Prochnicka-Chalufour A; Selz F; Picard C; Le Deist F; Eliaou JF; Fischer A; Lisowska-Grospierre B
Immunogenetics; 2003 Feb; 54(11):747-55. PubMed ID: 12618906
[TBL] [Abstract][Full Text] [Related]
6. A gene encoding a novel RFX-associated transactivator is mutated in the majority of MHC class II deficiency patients.
Masternak K; Barras E; Zufferey M; Conrad B; Corthals G; Aebersold R; Sanchez JC; Hochstrasser DF; Mach B; Reith W
Nat Genet; 1998 Nov; 20(3):273-7. PubMed ID: 9806546
[TBL] [Abstract][Full Text] [Related]
7. Down-regulation of MHC class II expression through inhibition of CIITA transcription by lytic transactivator Zta during Epstein-Barr virus reactivation.
Li D; Qian L; Chen C; Shi M; Yu M; Hu M; Song L; Shen B; Guo N
J Immunol; 2009 Feb; 182(4):1799-809. PubMed ID: 19201831
[TBL] [Abstract][Full Text] [Related]
8. Three novel mutations of the CIITA gene in MHC class II-deficient patients with a severe immunodeficiency.
Dziembowska M; Fondaneche MC; Vedrenne J; Barbieri G; Wiszniewski W; Picard C; Cant AJ; Steimle V; Charron D; Alca-Loridan C; Fischer A; Lisowska-Grospierre B
Immunogenetics; 2002 Feb; 53(10-11):821-9. PubMed ID: 11862382
[TBL] [Abstract][Full Text] [Related]
9. Collagen and major histocompatibility class II expression in mesenchymal cells from CIITA hypomorphic mice.
Xu Y; McDonald J; Perloff E; Butticè G; Schreiber BM; Smith BD
Mol Immunol; 2007 Mar; 44(7):1709-21. PubMed ID: 16982097
[TBL] [Abstract][Full Text] [Related]
10. A functionally essential domain of RFX5 mediates activation of major histocompatibility complex class II promoters by promoting cooperative binding between RFX and NF-Y.
Villard J; Peretti M; Masternak K; Barras E; Caretti G; Mantovani R; Reith W
Mol Cell Biol; 2000 May; 20(10):3364-76. PubMed ID: 10779326
[TBL] [Abstract][Full Text] [Related]
11. CIITA leucine-rich repeats control nuclear localization, in vivo recruitment to the major histocompatibility complex (MHC) class II enhanceosome, and MHC class II gene transactivation.
Hake SB; Masternak K; Kammerbauer C; Janzen C; Reith W; Steimle V
Mol Cell Biol; 2000 Oct; 20(20):7716-25. PubMed ID: 11003667
[TBL] [Abstract][Full Text] [Related]
12. Transcriptional silencing of RFXAP in MHC class II-deficiency.
van Eggermond MC; Tezcan I; Heemskerk MH; van den Elsen PJ
Mol Immunol; 2008 May; 45(10):2920-8. PubMed ID: 18336911
[TBL] [Abstract][Full Text] [Related]
13. Identification of the ankyrin repeat proteins ANKRA and RFXANK as novel partners of class IIa histone deacetylases.
Wang AH; Grégoire S; Zika E; Xiao L; Li CS; Li H; Wright KL; Ting JP; Yang XJ
J Biol Chem; 2005 Aug; 280(32):29117-27. PubMed ID: 15964851
[TBL] [Abstract][Full Text] [Related]
14. Associations and interactions between bare lymphocyte syndrome factors.
DeSandro AM; Nagarajan UM; Boss JM
Mol Cell Biol; 2000 Sep; 20(17):6587-99. PubMed ID: 10938133
[TBL] [Abstract][Full Text] [Related]
15. Transcriptional regulation of the mouse PNRC2 promoter by the nuclear factor Y (NFY) and E2F1.
Zhou D; Masri S; Ye JJ; Chen S
Gene; 2005 Nov; 361():89-100. PubMed ID: 16181749
[TBL] [Abstract][Full Text] [Related]
16. Class II transactivator promoter activity is suppressed through regulation by a trophoblast noncoding RNA.
Geirsson A; Paliwal I; Lynch RJ; Bothwell AL; Hammond GL
Transplantation; 2003 Jul; 76(2):387-94. PubMed ID: 12883198
[TBL] [Abstract][Full Text] [Related]
17. Promoter-specific functions of CIITA and the MHC class II enhanceosome in transcriptional activation.
Masternak K; Reith W
EMBO J; 2002 Mar; 21(6):1379-88. PubMed ID: 11889043
[TBL] [Abstract][Full Text] [Related]
18. Assembly of major histocompatibility complex (MHC) class II transcription factors: association and promoter recognition of RFX proteins.
Burd AL; Ingraham RH; Goldrick SE; Kroe RR; Crute JJ; Grygon CA
Biochemistry; 2004 Oct; 43(40):12750-60. PubMed ID: 15461447
[TBL] [Abstract][Full Text] [Related]
19. The locus control region of the MHC class II promoter acts as a repressor element, the activity of which is inhibited by CIITA.
Serrat N; Serra-Sarasa M; Barrachina M; Lloberas J; Celada A
Mol Immunol; 2010 Jan; 47(4):825-32. PubMed ID: 19897249
[TBL] [Abstract][Full Text] [Related]
20. The transcription factor RFX protects MHC class II genes against epigenetic silencing by DNA methylation.
Seguín-Estévez Q; De Palma R; Krawczyk M; Leimgruber E; Villard J; Picard C; Tagliamacco A; Abbate G; Gorski J; Nocera A; Reith W
J Immunol; 2009 Aug; 183(4):2545-53. PubMed ID: 19620312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
